Research
Hormonal
GLP-1 agonists had a good safety profile with most adverse effects being mild.
GLP-1 agonists can be considered a safe option for weight management in obese IBD patients.
StrongSupportsmedium confidence
Most adverse effects were mild, and the IBD activity had no significant changes.
Why this rating
Based on the retrospective analysis of a specific patient cohort.
Source
Effectiveness and safety of GLP-1 agonist in obese patients with inflammatory bowel disease
Clara Ramos Belinchón et al. · Revista Española de Enfermedades Digestivas · 2024
cohort · n=16Cited 12×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →